In the long human struggle against lung cancer — a disease that claims hundreds of thousands of lives each year — a Chinese biotech has reached a meaningful threshold. Sichuan Kelun-Biotech announced that its antibody-drug conjugate sac-TMT, combined with Merck's immunotherapy Keytruda, outperformed Keytruda alone in slowing disease progression among patients with advanced non-small cell lung cancer carrying the PD-L1 marker. It is the first time a drug of this class has cleared a late-stage trial in this setting, opening a potential new path for patients who have long needed more options at t
The Manila Times
· Nov 24, 2025
· health
· 3 min read
High
Sourcing: Characterized
Kelun-Biotech's sac-TMT combo meets Phase III lung cancer trial primary endpoint
Potential to improve survival outcomes for patients with advanced non-small cell lung cancer, a leading cause of cancer mortality globally.
◉
Health & Medicine
7994 related articles
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 100% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Canada faces new COVID epidemic, not third wave, as variants target di…
The Globe and Mail · 99% match
Researchers identify new Ebola variant, propose repurposed drug treatm…
Medical Xpress · 99% match
Dalhousie researchers identify new Ebola variant, propose repurposed d…
Education News Canada · 99% match
Related Coverage
The Guardian · Aug 18
ADHD diagnosis surge raises questions about identity versus disorder
Experts warn that rising ADHD diagnoses increasingly reflect identity-seeking rather than medical need, with poor-qualit…
BBC News · Aug 18 BBC investigation expands: 30 children feared conceived with wrong donors at Cyprus IVF clinicsAt least 30 children, mostly British, are feared conceived via IVF in northern Cyprus using wrong sperm or egg donors th…
News-Medical · Aug 18 IV Iron Use Among Australian Women Surges 17-Fold in DecadeAustralian women's intravenous iron use jumped 17-fold in a decade, with 1 in 20 reproductive-age women receiving treatm…
geneonline.com · Aug 18 1 in 20 Australian Women Now Receiving IV Iron InfusionsOne in 20 Australian women now receive intravenous iron infusions, marking a significant decade-long increase in this tr…
Bias & Framing
⚖
Press release presented as news with promotional language emphasizing drug efficacy milestones; minimal critical analysis or independent verification of claims.
Bias Direction
center-right
Confidence
HIGH
Corporate announcement framing - article is structured as direct company press release (PRNewswire) with celebratory language about 'firsts' and 'milestones' without editorial scrutiny or counterbalance.
statistically significant and clinically meaningful improvement
first Phase III clinical trial of ADC combined with immune checkpoint inhibitor to achieve its primary endpoint
dual benefits
positive trend
achieved this milestone
Independent medical expert commentary on trial results
Comparative efficacy data versus other competing treatments
Potential limitations or adverse effects discussion
Cost-effectiveness or accessibility considerations
Regulatory expert perspective on approval timeline
Patient outcome data or real-world effectiveness evidence
Competing drug developers' responses or alternative approaches
Geopolitical Impact
🌎
Chinese biotech Kelun-Biotech's drug combo with Merck's Keytruda achieves lung cancer trial success, advancing China's pharmaceutical innovation and potentially reducing Western drug dependency in oncology.
Escalation Risk
low
Confidence
HIGH
China
United States
European Union
Asia-Pacific
Represents shift in pharmaceutical R&D capability toward China; strengthens Kelun-Biotech's market position and Chinese healthcare autonomy; maintains Merck's relevance through partnership but signals emerging competition in oncology space from Chinese innovators.
Similar to India's generic drug rise in 2000s-2010s, demonstrating how emerging economies develop indigenous pharmaceutical capabilities to reduce reliance on Western drug monopolies and reshape global healthcare markets.
Economic Lens
📈
Kelun-Biotech's sac-TMT combined with Merck's Keytruda achieved Phase III primary endpoints for lung cancer, positioning the company for market expansion and potential revenue growth in oncology therapeutics.
Market Signal
bullish
Confidence
HIGH
Biopharmaceuticals
Oncology/Cancer Treatment
Healthcare
Medical Devices & Diagnostics
Patients with advanced lung cancer gain access to a potentially more effective first-line treatment option combining ADC and immunotherapy, though availability and affordability depend on regulatory approval and pricing decisions in different markets.
Chinese regulatory authorities (CDE/NMPA) will likely expedite review of the supplemental new drug application given positive Phase III data. International regulators may follow with accelerated pathways. Pricing negotiations with healthcare systems will intensify as combination therapies typically command premium pricing.